Pure Global AI
NCT05877651Completed

MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.

A Single-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
SYZ Cell Therapy Co..Phase 1ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
MASCT-I injection
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
SYZ Cell Therapy Co..
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 21, 2020
End date
Oct 15, 2021
Enrollment
22 participants
Primary outcome

Adverse events and serious adverse events related to MASCT-I

Summary

The purpose of this study is to evaluate the safety and tolerability of MASCT-I in patients
 with metastatic or recurrent solid tumors who failed standard therapy.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05877651
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05877651 through Pure Global AI's free database. This Phase 1 trial is sponsored by SYZ Cell Therapy Co.. and is currently Completed. The study focuses on Solid Tumors. Target enrollment is 22 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.